Speaker Profile
M.D., Director of GRU Cancer Center, Augusta University
Biography
Dr. Khleif received his Medical Degree from the University of Amman in Amman, Jordon, and completed his residency at the Medical College of Ohio in Toledo, OH. Dr. Khleif joined the National Cancer Institute as a medical oncology fellow, becoming a senior investigator and Chief of Cancer Vaccine Section at the NCI. He also served as a Special Assistant to the Commissioner of the Food and Drug Administration, leading the Critical Path Initiative for oncology. Dr. Khleif served as the Director General and CEO of the King Hussein Cancer Center as part of an agreement between the NCI and Jordan. In 2007, Dr. Khleif was appointed, as part of a new agreement between the Health and Human Services Department/NCI and Jordan to develop this new Institute as a comprehensive cancer center and Biotechnology research hub for the Middle East. Dr. Khleif’s research interest is in identifying new and improved strategies to enhance specific immune response against cancer for preventive and therapeutic intent.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. We will hear from both industry and medical representatives about their novel and innovative programs, which have the goal of expediting immunotherapy cancer treatments and delivering better patient outcomes.
